Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees.  Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

Eli Lilly & Co. terlibat dalam penemuan, pengembangan, serta produksi dan penjualan produk farmasi. Perusahaan ini berkantor pusat di Indianapolis, Indiana dan saat ini mempekerjakan 47.000 karyawan penuh waktu. Produk kesehatan kardiometaboliknya termasuk Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, dan lainnya; Humulin, Humulin 70/30, dan lainnya; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, dan VERVE-301. Produk onkologinya termasuk Cyramza, Erbitux, Tyvyt, dan Verzenio. Produk imunnya termasuk Ebglyss, Olumiant, Omvoh, dan Taltz. Produk neurosciencenya termasuk Emgality dan Kisunla. Perusahaan ini juga terlibat dalam upaya penemuan, pengembangan, dan produksi radiofarmasi, serta terapi radioligan klinis dan pra-klinis yang sedang dikembangkan untuk pengobatan kanker. Perusahaan ini juga sedang mengembangkan inhibitor kecil molekul oral dari integrin a4b7 untuk penyakit radang usus (IBD). Perusahaan ini sedang mengevaluasi kandidat terapi gen novelnya, ixoberogene soroparvovec.

Eli Lilly

Google

Apple

Microsoft

Amazon

Broadcom

Meta Platforms

JPMorgan

Oracle

Exxon Mobil

Johnson & Johnson

ASML

MasterCard

SPDR S&P500 ETF

Palantir

Costco

Bank of America

General Electric

Procter & Gamble

Vanguard Total Stock Market ETF

Toyota

Caterpillar

AstraZeneca

Cisco

Goldman Sachs

Lam Research

Wells Fargo

Merck

Novo Nordisk

Novartis

Raytheon Technologies

Philip Morris

Applied Materials

American Express

Royal Bank of Canada

Intel

Abbott

Salesforce

Shell

T-Mobile

Intuitive Surgical

Disney

Shopify

Invesco QQQ Trust

Blackstone

PepsiCo

Boeing

Charles Schwab

Amgen

QUALCOMM

Texas Instruments

S&P Global

Verizon

Arista Networks

Lowe's

Capital One

Southern Copper

Honeywell

Sony

Pfizer

Unilever

Deere

TotalEnergies

ServiceNow

Adobe

Palo Alto Networks

ConocoPhillips

Medtronic

Progressive

Chubb

CrowdStrike

Sanofi

Vertex Pharmaceuticals

Bristol-Myers Squibb

Comcast

Vanguard Dev Markets ETF

Mercadolibre

Starbucks

Enbridge

Carvana

Agnico Eagle

General Dynamics

Vanguard Value ETF

Robinhood

Moody's

Nike

Northrop Grumman

Vanguard Total Bond Market ETF

Duke Energy

Scotiabank

Barclays

Doordash Inc

Marsh & McLennan

NetEase

Saham Eli Lilly

Tentang Eli Lilly

Statistik Kunci